31st Annual Piper Jaffray Healthcare Conference
The company participated in a fireside chat on Tuesday, December 3, 2019 at 11:00 a.m. Eastern Time in New York, NY.
To access a recording of audio webcast, click here
The company participated in a fireside chat on Tuesday, December 3, 2019 at 11:00 a.m. Eastern Time in New York, NY.
To access a recording of audio webcast, click here
The company presented on Wednesday, November 20, 2019 at 4:40 p.m. Greenwich Mean Time in London, UK. To access a recording of audio webcast, click here
The Company hosted a conference call and live audio webcast on October 30, 2019, at 5:00 pm Eastern Time. To access a recording of this conference call, click here
The company presented on Friday, October 4, 2019 at 10:05 a.m. Eastern Time in New York, N.Y. To access recording of the audio webcast, click here
The Company hosted an Investor Event on Saturday, September 28, 2019 at 6:30 p.m. Central European Summer Time (12:30 p.m. ET) in Barcelona, Spain, during the ESMO Congress 2019. To access recording of the webcast, click here
The Company participated in a fireside chat on Monday, September 9, 2019 at 11:40 a.m. Eastern Time. To access recording of audio webcast, click here
The Company participated in a fireside chat on Wednesday, September 4, 2019 at 1:15 p.m. Eastern Time. To access recording of audio webcast, click here
The Company hosted a conference call and live audio webcast on August 7, 2019, at 5:00 pm Eastern Time. To access a recording of this conference call, click here
We have assembled significant expertise in antibody engineering, particularly proprietary CDR-grafting methods, antibody production and formulation, immunochemistry, molecular biology, antibody conjugation, peptide chemistry, synthetic organic chemistry, and protein engineering.
Our Science
We believe that each of our antibodies has therapeutic potential either when administered as a naked antibody or when conjugated with therapeutic radioisotopes (radiolabeled), chemotherapeutics, cytokines or other toxins to create unique and potentially more effective treatment options.
Learn MoreImmunomedics is sponsoring an international Phase 3 clinical trial in patients with relapsed triple-negative breast cancer who have previously received two or more therapies for their metastatic disease.
